Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Total Debt (2018 - 2022)

Historic Total Debt for Theravance Biopharma (TBPH) over the last 5 years, with Q2 2022 value amounting to $396.1 million.

  • Theravance Biopharma's Total Debt rose 369.49% to $396.1 million in Q2 2022 from the same period last year, while for Jun 2022 it was $396.1 million, marking a year-over-year increase of 369.49%. This contributed to the annual value of $388.3 million for FY2021, which is 99.64% down from last year.
  • Theravance Biopharma's Total Debt amounted to $396.1 million in Q2 2022, which was up 369.49% from $393.2 million recorded in Q1 2022.
  • In the past 5 years, Theravance Biopharma's Total Debt ranged from a high of $396.1 million in Q2 2022 and a low of $229.2 million during Q4 2019
  • Over the past 5 years, Theravance Biopharma's median Total Debt value was $382.0 million (recorded in 2021), while the average stood at $334.0 million.
  • Its Total Debt has fluctuated over the past 5 years, first skyrocketed by 7115.66% in 2020, then crashed by 99.64% in 2021.
  • Theravance Biopharma's Total Debt (Quarter) stood at $229.5 million in 2018, then dropped by 0.17% to $229.2 million in 2019, then skyrocketed by 71.16% to $392.2 million in 2020, then fell by 1.0% to $388.3 million in 2021, then grew by 2.02% to $396.1 million in 2022.
  • Its last three reported values are $396.1 million in Q2 2022, $393.2 million for Q1 2022, and $388.3 million during Q4 2021.